Sector News

SVB buys Leerink for $280M, boosting its life sciences business

November 15, 2018
Life sciences

There’s a lot of talk at the moment about the emerging overlap between the tech and life sciences sectors, and now there’s a big player with extensive expertise in both areas.

Silicon Valley Bank parent SVB is buying prominent life sciences investor Leerink Partners for $280 million to create SVB Leerink, a company that SVB’s CEO Greg Becker said will deliver “a complete capital markets offering.”

That includes “debt, convertible debt and equity financing as well as advisory services—including mergers & acquisitions—for private and public healthcare and life science companies,” he added.

SVB is already active in both tech and life sciences; its clients include around half the venture capital backed companies in these sectors in the U.S., but adding Leerink will give it a big gain in life sciences, particularly in research and advisory expertise. It will also add prominent experts such as Geoffrey Porges, Andrew Berens and Joseph Schwartz.

The deal includes a $60 million fund to retain employees after the acquisition goes through that will be paid out over the following five years, and SVB said “key employees” have already signed employment and retention agreements.

Adding Leerink will diversify SVB’s revenue streams and boost noninterest income, according to SVB. In the 12 months to end-September, Leerink’s noninterest income was $263 million, while SVB booked $711 million, with the bulk of its income (more than $1.7 billion) coming from net interest. They don’t envisage any cost savings from the merger.

The deal is expected to close early next year, after which SVB Leerink will act as a wholly owned subsidiary of SVB and the leadership team will remain in place, with Leerink CEO Jeff Leerink taking the same role.

“This merger represents an important step forward for our firm as we continue to strive to be an indispensable company-building partner to our expanding global client base,” said Leerink.

“SVB and Leerink share a strong client-focused culture, uniquely aligned on building long-term client relationships.”

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.